Q-omics provides the consensus-scored SELENOTP2 profile across patient tissues and cancer cell-line models. SELENOTP2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SELENOTP2 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, SELENOTP2 RNA expression shows 5,668 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, COAD, and STAD as cancer lineages where SELENOTP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SELENOTP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SELENOTP2 survival associations across molecular data types. SELENOTP2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SELENOTP2 RNA expression–survival associations across cancer types. High SELENOTP2 expression shows unfavorable associations in UCEC, ESCA, MESO, STAD and BLCA, but favorable associations in LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SELENOTP2 RNA expression.
This table summarizes SELENOTP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SELENOTP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SELENOTP2 shows higher tumor expression in COAD. The COAD box plot shows higher SELENOTP2 RNA expression in tumor versus normal tissue (log2 FC = +0.189, t-test p = .008).
This table shows molecular features associated with SELENOTP2 in patient tissues and cancer cell lines. In patient samples, SELENOTP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
